Cingulate Inc.(CING)

Biotechnology · Kansas City, KS

$4.92+0.17 (+3.58%)

Delayed quote: Oct 6, 2026, 10:50 AM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T14:51:26.755Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:51:26.755Z.

Quote observation: 2026-10-06T14:50:18.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 66,267,657
Total debt · period ending 2026-06-30: 6,290,880
Cash · period ending 2026-06-30: 28,402,819
TTM revenue · period ending 2026-06-30: 0

FMP input reference: f1b6469add1457cabf137e6e5cfb012e486d3d2c84b47330ed8a9effb8bf14c7

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CING EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

CING Competitors' EV/Sales Ratio

CING

Cingulate Inc.

Current

Market Cap

$66.27M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GOSS

Gossamer Bio, Inc.

vs CING

Market Cap

$64.94M

EV/Sales Ratio

1.18x

TTM Avg

9.45x

3Y Avg

7.55x

5Y Avg

7.55x

FBIO

Fortress Biotech, Inc.

vs CING

Market Cap

$67.60M

EV/Sales Ratio

N/A

TTM Avg

1.19x

3Y Avg

0.71x

5Y Avg

0.83x

HRTX

Heron Therapeutics, Inc.

vs CING

Market Cap

$64.71M

EV/Sales Ratio

1.27x

TTM Avg

1.74x

3Y Avg

2.85x

5Y Avg

4.03x

INCR

InterCure Ltd.

vs CING

Market Cap

$64.68M

EV/Sales Ratio

1.35x

TTM Avg

1.24x

3Y Avg

1.42x

5Y Avg

1.83x

IBIO

iBio, Inc.

vs CING

Market Cap

$68.49M

EV/Sales Ratio

142.90x

TTM Avg

409.50x

3Y Avg

278.27x

5Y Avg

209.69x

KLRS

Kalaris Therapeutics Inc

vs CING

Market Cap

$63.30M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CSBR

Champions Oncology, Inc.

vs CING

Market Cap

$69.26M

EV/Sales Ratio

1.25x

TTM Avg

1.43x

3Y Avg

1.60x

5Y Avg

1.76x

ALPS

Alps Group Inc

vs CING

Market Cap

$63.23M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDSB

PDS Biotechnology Corporation

vs CING

Market Cap

$61.79M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Cingulate Inc. (CING)	$66.27M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$64.94M	1.18x	9.45x	7.55x	7.55x
Fortress Biotech, Inc. (FBIO)vs ›	$67.60M	N/A	1.19x	0.71x	0.83x
Heron Therapeutics, Inc. (HRTX)vs ›	$64.71M	1.27x	1.74x	2.85x	4.03x
InterCure Ltd. (INCR)vs ›	$64.68M	1.35x	1.24x	1.42x	1.83x
iBio, Inc. (IBIO)vs ›	$68.49M	142.90x	409.50x	278.27x	209.69x
Kalaris Therapeutics Inc (KLRS)vs ›	$63.30M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.26M	1.25x	1.43x	1.60x	1.76x
Alps Group Inc (ALPS)vs ›	$63.23M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$61.79M	N/A	N/A	N/A	N/A

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics